Gene therapy provides a promising way to treat inherited and acquired diseases via transfer of genetic material. The advancement of viral-vector gene therapies has enabled the industry to evolve and refine manufacturing scale-up approaches to generate viral vectors for a multitude of applications and target cells.
In this knowledge culture basic education series on lentiviral vectors, we delve further into principles of lentiviral transduction and challenges in suspension-based lentivirus production as well as lentiviral vector purification and associated analytics.
Learning objectives
- Principles of lentiviral transduction
- Lentiviral transduction for gene modification
- Suspension-based lentivirus production
- Lentivirus purification challenges
- Regulatory guidance on viral vector titer
Speaker:
Ilgyun Im, Ph.D.
Field Application Scientist, Cell and Gene Therapy, Thermo Fisher Scientific
Dr. Ilgyun Im holds a Ph.D. degree in stem cell biology from KAIST, S. Korea. Prior to joining in Thermo Fisher Scientific, he was a senior scientist at NetTargets and worked for AI-enhanced systems biology technologies for drug discovery platform. Before that, he had five years of post-doctoral experience at KRIBB and KIT in stem cell-based therapeutics and organoid development. Now Dr. Im oversees the production of closed automated systems, consumables, and reagents for CGT to help customers who are developing their pipelines.
Please complete the form below to access the webinar.